Trattamento del carcinoma ovarico con interferone α2b somministrato per via intraperitoneale

Translated title of the contribution: Intraperitoneal interferon α2b treatment of ovarian carcinoma

D. Ambrosio, L. Piscopo, C. Lauro, M. Rotondi, E. Gallo, F. Balbi

Research output: Contribution to journalArticle

Abstract

Background. Pharmacokinetic studies have confirmed that for many chemotherapeutic agents a substantial pharmacological advantage can be achieved using the intraperitoneal route. Aim of this study is to evaluate the efficacy of intraperitoneal interferon α2b chemotherapy to treat ovarian cancer. Methods. Forty-four patients affected by ovarian cancer have been submitted to intraperitoneal interferon α2b chemotherapy from October 1989 to May 1996 at the Gynecology and Obstetric Institute of the Second University of Naples. Intraperitoneal route has been obtained through a catheter in left iliac fossa. Drugs have been solved in 2000 ml of physiologic solution to obtain a better distribution into the peritoneal fluid. Results. Three patients of 15 not-pre-medicated and 16 of 24 pre-medicated have obtained complete anatomo-pathological resolution. No complicances have been checked about catheter. Only two patients have stopped the therapy for asthenia; all the others have well tolerated interferon. Conclusions. Our study shows the very low toxicity of interferon associated to a good tolerance of the intraperitoneal catheter and therefore we retain that intraperitoneal chemotherapy with interferon α2b improves the prognosis of patients with minimal ovarian cancer after systemical chemotherapy.

Original languageItalian
Pages (from-to)67-71
Number of pages5
JournalMinerva Ginecologica
Volume53
Issue number1 SUPPL. 1
Publication statusPublished - Feb 2001

Fingerprint

Interferons
Carcinoma
Ovarian Neoplasms
Drug Therapy
Catheters
Therapeutics
Asthenia
Ascitic Fluid
Gynecology
Obstetrics
Pharmacokinetics
Pharmacology
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

Ambrosio, D., Piscopo, L., Lauro, C., Rotondi, M., Gallo, E., & Balbi, F. (2001). Trattamento del carcinoma ovarico con interferone α2b somministrato per via intraperitoneale. Minerva Ginecologica, 53(1 SUPPL. 1), 67-71.

Trattamento del carcinoma ovarico con interferone α2b somministrato per via intraperitoneale. / Ambrosio, D.; Piscopo, L.; Lauro, C.; Rotondi, M.; Gallo, E.; Balbi, F.

In: Minerva Ginecologica, Vol. 53, No. 1 SUPPL. 1, 02.2001, p. 67-71.

Research output: Contribution to journalArticle

Ambrosio, D, Piscopo, L, Lauro, C, Rotondi, M, Gallo, E & Balbi, F 2001, 'Trattamento del carcinoma ovarico con interferone α2b somministrato per via intraperitoneale', Minerva Ginecologica, vol. 53, no. 1 SUPPL. 1, pp. 67-71.
Ambrosio D, Piscopo L, Lauro C, Rotondi M, Gallo E, Balbi F. Trattamento del carcinoma ovarico con interferone α2b somministrato per via intraperitoneale. Minerva Ginecologica. 2001 Feb;53(1 SUPPL. 1):67-71.
Ambrosio, D. ; Piscopo, L. ; Lauro, C. ; Rotondi, M. ; Gallo, E. ; Balbi, F. / Trattamento del carcinoma ovarico con interferone α2b somministrato per via intraperitoneale. In: Minerva Ginecologica. 2001 ; Vol. 53, No. 1 SUPPL. 1. pp. 67-71.
@article{af5a47cb4342427b84a75aab82fd9ffe,
title = "Trattamento del carcinoma ovarico con interferone α2b somministrato per via intraperitoneale",
abstract = "Background. Pharmacokinetic studies have confirmed that for many chemotherapeutic agents a substantial pharmacological advantage can be achieved using the intraperitoneal route. Aim of this study is to evaluate the efficacy of intraperitoneal interferon α2b chemotherapy to treat ovarian cancer. Methods. Forty-four patients affected by ovarian cancer have been submitted to intraperitoneal interferon α2b chemotherapy from October 1989 to May 1996 at the Gynecology and Obstetric Institute of the Second University of Naples. Intraperitoneal route has been obtained through a catheter in left iliac fossa. Drugs have been solved in 2000 ml of physiologic solution to obtain a better distribution into the peritoneal fluid. Results. Three patients of 15 not-pre-medicated and 16 of 24 pre-medicated have obtained complete anatomo-pathological resolution. No complicances have been checked about catheter. Only two patients have stopped the therapy for asthenia; all the others have well tolerated interferon. Conclusions. Our study shows the very low toxicity of interferon associated to a good tolerance of the intraperitoneal catheter and therefore we retain that intraperitoneal chemotherapy with interferon α2b improves the prognosis of patients with minimal ovarian cancer after systemical chemotherapy.",
keywords = "Chemotherapy, Interferon, Ovarian carcinoma",
author = "D. Ambrosio and L. Piscopo and C. Lauro and M. Rotondi and E. Gallo and F. Balbi",
year = "2001",
month = "2",
language = "Italian",
volume = "53",
pages = "67--71",
journal = "Minerva Ginecologica",
issn = "0026-4784",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "1 SUPPL. 1",

}

TY - JOUR

T1 - Trattamento del carcinoma ovarico con interferone α2b somministrato per via intraperitoneale

AU - Ambrosio, D.

AU - Piscopo, L.

AU - Lauro, C.

AU - Rotondi, M.

AU - Gallo, E.

AU - Balbi, F.

PY - 2001/2

Y1 - 2001/2

N2 - Background. Pharmacokinetic studies have confirmed that for many chemotherapeutic agents a substantial pharmacological advantage can be achieved using the intraperitoneal route. Aim of this study is to evaluate the efficacy of intraperitoneal interferon α2b chemotherapy to treat ovarian cancer. Methods. Forty-four patients affected by ovarian cancer have been submitted to intraperitoneal interferon α2b chemotherapy from October 1989 to May 1996 at the Gynecology and Obstetric Institute of the Second University of Naples. Intraperitoneal route has been obtained through a catheter in left iliac fossa. Drugs have been solved in 2000 ml of physiologic solution to obtain a better distribution into the peritoneal fluid. Results. Three patients of 15 not-pre-medicated and 16 of 24 pre-medicated have obtained complete anatomo-pathological resolution. No complicances have been checked about catheter. Only two patients have stopped the therapy for asthenia; all the others have well tolerated interferon. Conclusions. Our study shows the very low toxicity of interferon associated to a good tolerance of the intraperitoneal catheter and therefore we retain that intraperitoneal chemotherapy with interferon α2b improves the prognosis of patients with minimal ovarian cancer after systemical chemotherapy.

AB - Background. Pharmacokinetic studies have confirmed that for many chemotherapeutic agents a substantial pharmacological advantage can be achieved using the intraperitoneal route. Aim of this study is to evaluate the efficacy of intraperitoneal interferon α2b chemotherapy to treat ovarian cancer. Methods. Forty-four patients affected by ovarian cancer have been submitted to intraperitoneal interferon α2b chemotherapy from October 1989 to May 1996 at the Gynecology and Obstetric Institute of the Second University of Naples. Intraperitoneal route has been obtained through a catheter in left iliac fossa. Drugs have been solved in 2000 ml of physiologic solution to obtain a better distribution into the peritoneal fluid. Results. Three patients of 15 not-pre-medicated and 16 of 24 pre-medicated have obtained complete anatomo-pathological resolution. No complicances have been checked about catheter. Only two patients have stopped the therapy for asthenia; all the others have well tolerated interferon. Conclusions. Our study shows the very low toxicity of interferon associated to a good tolerance of the intraperitoneal catheter and therefore we retain that intraperitoneal chemotherapy with interferon α2b improves the prognosis of patients with minimal ovarian cancer after systemical chemotherapy.

KW - Chemotherapy

KW - Interferon

KW - Ovarian carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0034975692&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034975692&partnerID=8YFLogxK

M3 - Articolo

C2 - 11526725

AN - SCOPUS:0034975692

VL - 53

SP - 67

EP - 71

JO - Minerva Ginecologica

JF - Minerva Ginecologica

SN - 0026-4784

IS - 1 SUPPL. 1

ER -